These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 23355910)

  • 21. An Endocrine Perspective of Nonalcoholic Fatty Liver Disease (NAFLD).
    Lomonaco R; Chen J; Cusi K
    Ther Adv Endocrinol Metab; 2011 Oct; 2(5):211-25. PubMed ID: 23148186
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Molecular mechanisms of steatosis in nonalcoholic fatty liver disease.
    Pettinelli P; Obregón AM; Videla LA
    Nutr Hosp; 2011; 26(3):441-50. PubMed ID: 21892559
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pathogenesis of hepatocarcinogenesis in non-cirrhotic nonalcoholic fatty liver disease: Potential mechanistic pathways.
    Perumpail RB; Liu A; Wong RJ; Ahmed A; Harrison SA
    World J Hepatol; 2015 Oct; 7(22):2384-8. PubMed ID: 26464753
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Downregulated microRNA-130b-5p prevents lipid accumulation and insulin resistance in a murine model of nonalcoholic fatty liver disease.
    Liu X; Chen S; Zhang L
    Am J Physiol Endocrinol Metab; 2020 Jul; 319(1):E34-E42. PubMed ID: 32228319
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Interaction of metabolic syndrome, nonalcoholic fatty liver disease and chronic hepatitis C.
    Rafiq N; Younossi ZM
    Expert Rev Gastroenterol Hepatol; 2008 Apr; 2(2):207-15. PubMed ID: 19072356
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Nonalcoholic fatty liver disease: A main driver of insulin resistance or a dangerous liaison?
    Gruben N; Shiri-Sverdlov R; Koonen DP; Hofker MH
    Biochim Biophys Acta; 2014 Nov; 1842(11):2329-2343. PubMed ID: 25128743
    [TBL] [Abstract][Full Text] [Related]  

  • 27. From Nonalcoholic Fatty Liver Disease (NAFLD) to Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD)-New Terminology in Pediatric Patients as a Step in Good Scientific Direction?
    Flisiak-Jackiewicz M; Bobrus-Chociej A; Wasilewska N; Lebensztejn DM
    J Clin Med; 2021 Mar; 10(5):. PubMed ID: 33804296
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Hepatic insulin resistance in NAFLD: relationship with markers of atherosclerosis and metabolic syndrome components.
    Privitera G; Spadaro L; Alagona C; Calanna S; Piro S; Rabuazzo AM; Purrello F
    Acta Diabetol; 2016 Jun; 53(3):449-59. PubMed ID: 26496770
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Plasma adiponectin in nonalcoholic fatty liver is related to hepatic insulin resistance and hepatic fat content, not to liver disease severity.
    Bugianesi E; Pagotto U; Manini R; Vanni E; Gastaldelli A; de Iasio R; Gentilcore E; Natale S; Cassader M; Rizzetto M; Pasquali R; Marchesini G
    J Clin Endocrinol Metab; 2005 Jun; 90(6):3498-504. PubMed ID: 15797948
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Characterization of lean patients with nonalcoholic fatty liver disease: potential role of high hemoglobin levels.
    Akyuz U; Yesil A; Yilmaz Y
    Scand J Gastroenterol; 2015 Mar; 50(3):341-6. PubMed ID: 25540973
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Obstructive sleep apnea syndrome affects liver histology and inflammatory cell activation in pediatric nonalcoholic fatty liver disease, regardless of obesity/insulin resistance.
    Nobili V; Cutrera R; Liccardo D; Pavone M; Devito R; Giorgio V; Verrillo E; Baviera G; Musso G
    Am J Respir Crit Care Med; 2014 Jan; 189(1):66-76. PubMed ID: 24256086
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Vitamin D receptor targets hepatocyte nuclear factor 4α and mediates protective effects of vitamin D in nonalcoholic fatty liver disease.
    Zhang H; Shen Z; Lin Y; Zhang J; Zhang Y; Liu P; Zeng H; Yu M; Chen X; Ning L; Mao X; Cen L; Yu C; Xu C
    J Biol Chem; 2020 Mar; 295(12):3891-3905. PubMed ID: 32051143
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Update on nonalcoholic fatty liver disease: genes involved in nonalcoholic fatty liver disease and associated inflammation.
    Tilg H; Moschen A
    Curr Opin Clin Nutr Metab Care; 2010 Jul; 13(4):391-6. PubMed ID: 20473151
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Dietary Patterns Influence Target Gene Expression through Emerging Epigenetic Mechanisms in Nonalcoholic Fatty Liver Disease.
    Zaiou M; Amrani R; Rihn B; Hajri T
    Biomedicines; 2021 Sep; 9(9):. PubMed ID: 34572442
    [TBL] [Abstract][Full Text] [Related]  

  • 35. From the metabolic syndrome to NAFLD or vice versa?
    Vanni E; Bugianesi E; Kotronen A; De Minicis S; Yki-Järvinen H; Svegliati-Baroni G
    Dig Liver Dis; 2010 May; 42(5):320-30. PubMed ID: 20207596
    [TBL] [Abstract][Full Text] [Related]  

  • 36.
    Lisboa QC; Nardelli MJ; Pereira PA; Miranda DM; Ribeiro SN; Costa RSN; Versiani CA; Vidigal PVT; Ferrari TCA; Couto CA
    World J Hepatol; 2020 Oct; 12(10):792-806. PubMed ID: 33200017
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A Perspective on Metabolic Syndrome and Nonalcoholic Fatty Liver Disease.
    Targher G; Byrne CD
    Metab Syndr Relat Disord; 2015 Aug; 13(6):235-8. PubMed ID: 25714786
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Nonalcoholic Fatty Liver Disease in Children: Hepatic and Extrahepatic Complications.
    Selvakumar PKC; Kabbany MN; Nobili V; Alkhouri N
    Pediatr Clin North Am; 2017 Jun; 64(3):659-675. PubMed ID: 28502444
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The metabolic syndrome and nonalcoholic fatty liver disease in children.
    Sundaram SS; Zeitler P; Nadeau K
    Curr Opin Pediatr; 2009 Aug; 21(4):529-35. PubMed ID: 19444112
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Nonalcoholic Fatty Liver Disease and Type 2 Diabetes Mellitus.
    Dharmalingam M; Yamasandhi PG
    Indian J Endocrinol Metab; 2018; 22(3):421-428. PubMed ID: 30090738
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.